Aptose Biosciences is a clinical-stage biotechnology company developing personalized therapies to address unmet medical needs in oncology, with a particular focus on hematologic malignancies. Aptose is advancing new therapeutics focused on well validated and novel drug targets on the leading edge of cancer research, coupled with validated biomarkers to identify the optimal patient population for our products. The company's small molecule cancer therapeutics pipeline includes products designed for potent single agent activity and to enhance the efficacy of existing anti-cancer therapies without overlapping toxicities. Aptose Biosciences Inc. is listed on NASDAQ under the symbol APTO and on the TSX under the symbol APS.
Latest Investor Information
Recent Press Releases
| Receive Email Alerts|
|Sign up to receive email alerts whenever Aptose Biosciences, Inc. posts new information to the site. Just enter your email address and click Submit.|
|Data provided by Nasdaq. Minimum 15 minutes delayed.|